CMS Entry id: 2709 | Channel: Blog landing page | Template: blog/index

Login
Facebook YouTube Twitter Linkedin
Facebook YouTube Twitter Linkedin

Blog

Bringing a drug to market: How do we find and monitor suitable patients?

What will happen when we eventually develop a treatment that halts the development of early Alzheimer’s disease? Being first-in-class, pharmacovigilance post-marketing will be vitally important to ascertain the long-term effects of the drug: both positive and negative. We need to be prepared for a breakthrough and pre-emptively identify technologies which can find the right patients likely to benefit from the drug and monitor treatment effects in the real world. 

CANTAB technology selected for world’s largest dementia study

We are pleased to announce our partnership with Dementias Platform UK (DPUK), the world’s largest study group in dementia research formed to accelerate the development of effective, and ultimately preventative, treatments for diseases such as Alzheimer’s.

7 tests for assessing cognition in early Alzheimer’s disease

With rising life-expectancy, the number of cases of dementia and related disorders is increasing. In attempts to tackle the pandemic, treatment trials are moving earlier in the disease process. CANTAB offers a battery of tests specially targeted at assessing cognition in early Alzheimer’s disease (AD), and the associated effects on cognition with drug action

A solution for improving recruitment into early Alzheimer’s disease clinical trials

Screening patients into early stage Alzheimer’s trials can be costly and time-consuming. Kenton Zavitz, PhD, Director of Clinical Affairs proposes a potential solution for improving recruitment into clinical trials. 

The challenge of detecting early Alzheimer’s disease for clinical trials

In this post, Director of Clinical Affairs, Dr Kenton Zavitz, looks at the challenge of recruiting the correct patients into Alzheimer's disease trials.

What does the new FDA guidance mean for clinical trials in early Alzheimer’s disease?

The latest FDA draft guidance for clinical trials in early Alzheimer’s disease presents many new opportunities and challenges for drug development. 

WEBINAR: Finding the right patients for clinical trials in early Alzheimer's disease

Dr Kenton Zavitz, Director of Clinical Affairs at Cambridge Cognition, and Dr Robert Smith, Consultant Neuropsychologist, hosted a webinar to discuss clinical trials for early Alzheimer’s disease.

Join them to hear more about overcoming the barriers to expedite the drug development process.

Tuesday 22nd May 2018, 11 a.m. EDT

web-based testing, wearables, voice recognition, virtual clinical trials, transdiagnostic, test-retest, technology, swm, subjective measures, stigma, spatial planning, social cognition, smartphones, set-shifting, schizophrenia research, schizophrenia, rvp, rule learning, research funding, remote testing, regulations, recruitment, real-world assessments, prodromal, pro-cognitive, presenteeism, precision psychiatry, pre-clinical, pharmacovigilance, personalised medicine, patient-centric, patient screening, patient recruitment, parkinson's disease, pal, ots, opinion piece, occupational health, objective measures, novel, normative data, neurotech, neuroscience, near-patient testing, multiple sclerosis, ms, modelling, mental wellbeing, mental health, mci, major depression, machine learning, lifespan, inpatients, ied, high frequency, healthcare, ert, episodic memory, epidemiology, emotion recognition, efficacy, ecological momentary assessments, ebt, ebbinghaus, early alzheimer's disease, drug development, dopamine, digital tools, digital health, depression, dementia, cognitive testing, cognitive science, cognitive safety, cognitive impairment, cognitive function, cognitive dysfunction, cognitive deficits, cognitive biomarkers, cognitive assessment, cognition kit, cognition, cns summit, clinical trials, clinical trial, clinical symptoms, cias, cgt, cantab research grant, cantab for clinical trials, cantab, brain health, biomarkers, awards, automatic speech recognition, attention, alzheimer's disease, affective cognition, absenteeism,